MX2016009690A - Anticuerpos monoclonal anti-factor de tejido. - Google Patents
Anticuerpos monoclonal anti-factor de tejido.Info
- Publication number
- MX2016009690A MX2016009690A MX2016009690A MX2016009690A MX2016009690A MX 2016009690 A MX2016009690 A MX 2016009690A MX 2016009690 A MX2016009690 A MX 2016009690A MX 2016009690 A MX2016009690 A MX 2016009690A MX 2016009690 A MX2016009690 A MX 2016009690A
- Authority
- MX
- Mexico
- Prior art keywords
- tissue factor
- monoclonal antibody
- factor monoclonal
- antibody
- factor
- Prior art date
Links
- 102000002262 Thromboplastin Human genes 0.000 abstract 2
- 108010000499 Thromboplastin Proteins 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona nuevos anticuerpos contra factor de tejido. La presente invención también proporciona composiciones farmacéuticas en las cuales se usa un anticuerpo como un factor de unión a diana. Los anticuerpos de acuerdo a la presente invención pueden exhibir la capacidad de interiorizarse en células que expresan factor de tejido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014018586 | 2014-02-03 | ||
PCT/JP2015/052918 WO2015115656A1 (ja) | 2014-02-03 | 2015-02-03 | 抗Tissue Factorモノクローナル抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016009690A true MX2016009690A (es) | 2017-03-03 |
Family
ID=53757221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009690A MX2016009690A (es) | 2014-02-03 | 2015-02-03 | Anticuerpos monoclonal anti-factor de tejido. |
Country Status (11)
Country | Link |
---|---|
US (1) | US9920133B2 (es) |
EP (1) | EP3103811A4 (es) |
JP (1) | JP5957637B2 (es) |
KR (1) | KR20160136279A (es) |
CN (1) | CN106255703A (es) |
AU (1) | AU2015211674A1 (es) |
BR (1) | BR112016017010A2 (es) |
CA (1) | CA2937034A1 (es) |
MX (1) | MX2016009690A (es) |
TW (1) | TWI655211B (es) |
WO (1) | WO2015115656A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017028823A1 (zh) * | 2015-08-20 | 2017-02-23 | 复旦大学 | 靶向于组织因子的抗体、其制备方法和用途 |
AR107787A1 (es) * | 2016-03-02 | 2018-06-06 | Eisai Co Ltd | Conjugados de anticuerpos basados en eribulina y métodos de uso |
US10676537B2 (en) | 2016-08-22 | 2020-06-09 | Fudan University | Antibody targeted to tissue factor, preparation method therefor, and use thereof |
CN107446047B (zh) * | 2017-09-04 | 2020-08-11 | 山西省生物研究院有限公司 | 一种双功能性抗组织因子人源化抗体及其制备方法 |
TW201922796A (zh) | 2017-10-30 | 2019-06-16 | 國立研究開發法人國立癌症研究中心 | 可用於實體腫瘤治療之抗體及其抗體-藥物共軛物以及含其之抗癌劑 |
KR20200118029A (ko) * | 2018-01-04 | 2020-10-14 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
JP7407822B2 (ja) * | 2018-08-30 | 2024-01-04 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 単鎖キメラポリペプチドおよびその使用 |
JPWO2021200131A1 (es) | 2020-03-30 | 2021-10-07 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5093593A (en) * | 1992-08-28 | 1994-03-29 | Scripps Research Institute, The | Inhibition of tumor metastasis via neutralization of tissue factor function |
AU7949394A (en) | 1993-11-19 | 1995-06-06 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
JPH09302000A (ja) | 1996-05-16 | 1997-11-25 | Chemo Sero Therapeut Res Inst | 抗組織因子モノクローナル抗体及び当該モノクローナル抗体を用いた組織因子凝固活性の測定法 |
US20060235209A9 (en) | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US5986065A (en) | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
US20030124117A1 (en) | 2000-03-16 | 2003-07-03 | Refino Canio J. | Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents |
US6703494B2 (en) | 2000-03-16 | 2004-03-09 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
JP2003527861A (ja) * | 2000-03-16 | 2003-09-24 | ジェネンテック・インコーポレーテッド | 増強した抗血液凝固能を持つ抗組織因子抗体 |
US20030143225A1 (en) | 2001-03-08 | 2003-07-31 | Genentech, Inc. | Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents |
TWI338009B (en) * | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
US7425328B2 (en) | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
EP2582728B1 (en) | 2010-06-15 | 2017-08-23 | Genmab A/S | Human antibody drug conjugates against tissue factor |
CN108117586A (zh) | 2010-08-10 | 2018-06-05 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
US8722044B2 (en) | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
JP5897422B2 (ja) | 2012-07-23 | 2016-03-30 | 株式会社ニューギン | 遊技機 |
-
2015
- 2015-02-03 TW TW104103660A patent/TWI655211B/zh not_active IP Right Cessation
- 2015-02-03 WO PCT/JP2015/052918 patent/WO2015115656A1/ja active Application Filing
- 2015-02-03 CA CA2937034A patent/CA2937034A1/en not_active Abandoned
- 2015-02-03 CN CN201580006870.2A patent/CN106255703A/zh active Pending
- 2015-02-03 KR KR1020167021291A patent/KR20160136279A/ko not_active Application Discontinuation
- 2015-02-03 US US15/111,875 patent/US9920133B2/en active Active
- 2015-02-03 EP EP15743456.4A patent/EP3103811A4/en not_active Withdrawn
- 2015-02-03 JP JP2015555482A patent/JP5957637B2/ja active Active
- 2015-02-03 AU AU2015211674A patent/AU2015211674A1/en not_active Abandoned
- 2015-02-03 MX MX2016009690A patent/MX2016009690A/es unknown
- 2015-02-03 BR BR112016017010A patent/BR112016017010A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP3103811A4 (en) | 2017-11-29 |
WO2015115656A1 (ja) | 2015-08-06 |
US20160333113A1 (en) | 2016-11-17 |
BR112016017010A2 (pt) | 2017-10-03 |
TWI655211B (zh) | 2019-04-01 |
CA2937034A1 (en) | 2015-08-06 |
EP3103811A1 (en) | 2016-12-14 |
JP5957637B2 (ja) | 2016-07-27 |
CN106255703A (zh) | 2016-12-21 |
US9920133B2 (en) | 2018-03-20 |
AU2015211674A1 (en) | 2016-08-04 |
TW201613980A (en) | 2016-04-16 |
JPWO2015115656A1 (ja) | 2017-03-23 |
KR20160136279A (ko) | 2016-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201613980A (en) | Anti-tissue factor monoclonal antibody | |
MX2020009649A (es) | Anticuerpos monoclonales contra bcma. | |
PH12017502180A1 (en) | Tau-binding antibodies | |
PH12018500894A1 (en) | Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab | |
EP3423089A4 (en) | ANTI-Tigit ANTIBODY | |
EP4249515A3 (en) | Humanized or chimeric cd3 antibodies | |
TN2017000246A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
MX2016014862A (es) | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
PH12017502207A1 (en) | Tau-binding antibodies | |
SG10201909716RA (en) | Modified j-chain | |
AU2014247175A8 (en) | Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use | |
NZ761537A (en) | Anti-human ox40l antibodies, uses & methods | |
SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
EP3247718A4 (en) | MODULATION OF CHARGE VARIANTS IN A MONOCLONAL ANTIBODY COMPOSITION | |
MX2023006415A (es) | Anticuerpos, usos y metodos. | |
ZA201800804B (en) | Novel anti-human gpvi antibodies and uses thereof | |
EP3551228A4 (en) | ANTIBODIES FOR HUMAN ALPHA SYNUCLEIN | |
EP3510046A4 (en) | ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES | |
CU20170012A7 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
MX2016014416A (es) | Anticuerpos anti-her3 que se unen a la horquilla beta de her3. | |
EP3239177A4 (en) | Novel egfrviii antibody and composition comprising same | |
EP3231441A4 (en) | Novel protein structure produced by effective antibody used for immunization | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. |